Brief: Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea
31/05/2016 04:03
May 31 (Reuters) - Kaken Pharmaceutical Co Ltd 4521.T :
* Says Kaken Pharmaceutical 4521.T and A Korea-based firm
Dong-A ST Co Ltd 170900.KS concluded an exclusive distribution
agreement for the topical formulation for Onychomycosis
"Clenafin / Jublia" in Korea
* Says according to the agreement, Kaken hereby grant to
Dong-A the exclusive right for development and sales of the
Product in Korea
Source text in Japanese: https://goo.gl/TTVUJU
Further company coverage:[4521.T ] 170900.KS
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))